Heartseed Inc. — Biomedical Watch V2

Traitements5programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
HS-001 CSThe purpose of this clinical study is to evaluate the safety and efficacy of HS-001 CS transplanted into severe heart failure patients with underlying ischemic heart disease for 26 weeks after transplantation.	Insuffisance cardiaque, Maladie coronarienne	Phase 1/2	À vérifier	Japan	À vérifier
HS-001-D needle, HS-001-D AdaptorThe purpose of this clinical study is to evaluate the safety and efficacy of HS-001 CS transplanted into severe heart failure patients with underlying ischemic heart disease for 26 weeks after transplantation.	Insuffisance cardiaque, Maladie coronarienne	Phase 1/2	À vérifier	Japan	À vérifier
HS-005The purpose of this clinical study is to evaluate the safety and efficacy of endocardial delivery of HS-001 CS into severe heart failure patients with reduced ejection fraction for 26 weeks after transplantation.	Insuffisance cardiaque, Maladie coronarienne	Phase 1/2	À vérifier	Japan	À vérifier
HS-005The purpose of this clinical study is to evaluate the safety and efficacy of endocardial delivery of HS-001 CS into severe heart failure patients with reduced ejection fraction for 26 weeks after transplantation.	Insuffisance cardiaque	Phase 1/2	À vérifier	Japan	À vérifier
HS-001 CSThe purpose of this clinical study is to evaluate the safety and efficacy of HS-001 CS transplanted into severe heart failure patients with underlying ischemic heart disease for 26 weeks after transplantation.	Insuffisance cardiaque	Phase 1/2	À vérifier	Japan	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
HS-001 CS	Insuffisance cardiaque	Phase 1/2	NCT04945018	A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study)	COMPLETED
HS-005	Insuffisance cardiaque	Phase 1/2	NCT07347197	Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.